Gordonmd® invests in private placement for taysha gene therapies

Dallas--(business wire)--gordonmd® global investments lp announced today it has participated in a $150 million private placement financing for taysha gene therapies, inc. (nasdaq: tsha), a clinical-stage gene therapy company focused on developing and commercializing aav-based gene therapies for the treatment of monogenic diseases of the central nervous system (cns). net proceeds will be used primarily to fund clinical development of tsha-102 in rett syndrome and to provide support for program a.
TSHA Ratings Summary
TSHA Quant Ranking